These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 15266098

  • 1. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 2. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 3. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 5. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 01; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 7. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Jun 01; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Jun 01; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 9. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 01; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 10. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Jan 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 11. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P.
    Am J Health Syst Pharm; 2008 Sep 15; 65(18):1711-9. PubMed ID: 18768997
    [Abstract] [Full Text] [Related]

  • 12. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Sep 15; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 13. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, Larsson AM.
    Adv Ther; 2005 Sep 15; 22(3):208-24. PubMed ID: 16236682
    [Abstract] [Full Text] [Related]

  • 14. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 15; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.
    Oncologist; 2004 Jun 15; 9(4):459-68. PubMed ID: 15266099
    [Abstract] [Full Text] [Related]

  • 16. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Oct 25; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 18. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Oct 25; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 19. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC.
    J Nephrol; 2008 Oct 25; 21(4):543-9. PubMed ID: 18651544
    [Abstract] [Full Text] [Related]

  • 20. [Study of effectiveness of 3 schedules of administration of erythropoietic colony-stimulating factors in anemic patients under chemotherapy for solid or hematology malignancy].
    Pontón Sivillá JL, Feliu Frasnedo E, Modamio Charles P, Mariño Hernández EL, Font Pous A, Lezcano Rubio C, Ribera Santasusana JM, Bonafont Pujol X.
    Med Clin (Barc); 2008 Oct 11; 131(12):447-51. PubMed ID: 18928734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.